Elderly patients with metastatic colorectal cancer: first-line reduced-dose chemo plus targeted antibody

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis of first-line treatment patterns in patients aged 70 or older with metastatic colorectal adenocarcinoma. It describes the use of fixed or reduced-dose chemotherapy in combination with monoclonal antibody therapy, guided by tumor site and mutations (RAS/BRAF). The report discusses patient selection factors such as age, general condition, and G8 score that influence treatment intensity. The aim is to understand real-world practice and outcomes in a population for whom full-dose regimens often pose higher toxicity risk. Interventions and specific data collection methods are not prospectively defined in detail, as this is based on existing records.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.
2. Age ≥ 70 years
3. G8 score ≥ 12
4. Patients with colorectal adenocarcinoma MSS
5. Patients with BRAF WT colorectal adenocarcinoma
6. Ability to understand and sign the informed consent form.

Exclusion Criteria:

1. Patients with MSI tumours
2. Patients with BRAF V600E mutated tumours
3. Patients not eligible for doublet chemotherapy by clinical decision

Where it's running

• E.O. Ospedali Galliera
  Genova, Ge, Italy Recruiting
• E.O. Ospedali Galliera
  Genoa, Liguria, Italy Not yet recruiting

Study contacts

• Principal investigator: Matteo Clavarezza — E.O. Ospedali Galliera
• Study coordinator: Matteo Clavarezza
• Email: matteo.clavarezza@galliera.it
• Phone: 010.5634580

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Postoperative ctDNA Monitoring to Predict Recurrence in Driver-Mutant Stage I-III Colon Cancer

  This study tests whether checking blood tumor DNA after surgery can predict if driver-mutant stage I-III colon cancer will come back.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07795528

• Adding tolecizumab to chemoimmunotherapy before surgery for locally advanced pMMR/MSS colon cancer

  We're testing whether adding tolecizumab (a PCSK9 blocker) to sintilimab plus CapeOX before surgery helps people with pMMR/MSS locally advanced colon cancer (cT3c or higher) achieve a complete tumor response.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07468630

• Family genetics: who shares test results with relatives

  This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.

  Recruiting at 362 sites Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 364 other locations · NCT07143487

• Calderasib plus cetuximab and chemotherapy for KRAS G12C colorectal cancer

  This trial will test whether adding calderasib and cetuximab to mFOLFOX6 helps people with unresectable locally advanced or metastatic colorectal cancer that has a KRAS G12C mutation live longer without their cancer growing.

  Recruiting at 244 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 244 other locations · NCT06997497

• Testing a new stool test for colorectal cancer detection

  This study is testing a new stool test to see if it can help find colorectal cancer and advanced growths in people aged 45 and older who are at average risk.

  Recruiting Mainz Biomed · Morrisville, North Carolina · NCT06864338

• Using HDAC inhibitors with chemoimmunotherapy for advanced colon cancer treatment

  This study is testing if adding HDAC inhibitors to chemotherapy and immunotherapy can help people with advanced colon cancer have better treatment results and improve their chances of recovery.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06709885

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.